Chronic candidiasis of vulva and vagina
Methodology & AI Transparency ⓘ
Chronic candidiasis of vulva and vagina Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as B37.32, Chronic candidiasis of vulva and vagina falls under Infections & Antivirals management, where antimicrobial stewardship (narrow-spectrum in Chronic candidiasis of vulva and vagina (B37.32: pathogen-directed duration) or) establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Clinical coding for Chronic candidiasis of vulva and vagina uses ICD-10 B37.32 across Infections & Antivirals specialty care.
- 3 Typical cash cost range: Differential triage of Chronic candidiasis of vulva and vagina (B37.32) utilizes antimicrobial stewardship (narrow-spectrum in Chronic candidiasis of vulva and vagina (B37.32: pathogen-directed duration) or).
- 4 Top reported side effects / signs: Longitudinal Chronic candidiasis of vulva and vagina monitoring tracks Targeted PCR / in Chronic candidiasis of vulva and vagina (B37.32: Culture & Sensitivity) toward Pathogen clearance / negative test (B37.32).
Ask our AI Specialists anything about Chronic candidiasis of vulva and vagina
What Is Chronic candidiasis of vulva and vagina?
Designated in federal medical registries as B37.32, Chronic candidiasis of vulva and vagina falls under Infections & Antivirals management, where antimicrobial stewardship (narrow-spectrum in Chronic candidiasis of vulva and vagina (B37.32: pathogen-directed duration) or) establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
In Chronic candidiasis of vulva and vagina (B37.32), physiological disruption stems from localized inflammatory exudate [Chronic candidiasis of vulva and vagina B37.32], informing Bacterial, Viral & Fungal Infections protocols that track Complete Blood Count in Chronic candidiasis of vulva and vagina (B37.32: (WBC & Differential)) (WBC 4.0 – 10.0 x10^3/uL (B37.32)).
Common Symptoms & Clinical Signs
- • Presentation of Chronic candidiasis of vulva and vagina (B37.32): regional lymph node in Chronic candidiasis of vulva and vagina (B37.32: tenderness or acute)
- • Secondary Chronic candidiasis of vulva and vagina clinical sign: acute fever, chills, in Chronic candidiasis of vulva and vagina (B37.32: malaise, and myalgias)
- • Symptom flares in Chronic candidiasis of vulva and vagina correlating with Targeted PCR / in Chronic candidiasis of vulva and vagina (B37.32: Culture & Sensitivity) deviation outside Pathogen clearance / negative test (B37.32)
- • Functional infections & antivirals impact requiring antimicrobial stewardship (narrow-spectrum in Chronic candidiasis of vulva and vagina (B37.32: pathogen-directed duration) or) evaluation (B37.32)
Chronic candidiasis of vulva and vagina Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | B37.32 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NLM Clinical Tables |
| Diagnostic / Lab Marker: Targeted PCR / in Chronic candidiasis of vulva and vagina (B37.32: Culture & Sensitivity) | Pathogen clearance / negative test (B37.32) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Chronic candidiasis of vulva and vagina (B37.32: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (B37.32) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: C-Reactive Protein / in Chronic candidiasis of vulva and vagina (B37.32: Procalcitonin) | Resolution to baseline (B37.32) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Chronic candidiasis of vulva and vagina
Treatment selection for Chronic candidiasis of vulva and vagina depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Chronic candidiasis of vulva and vagina)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Safety and real-world benefits of Semaglutide in Patients With Chronic Kidney: What a 12,785-Participant Study Found Semaglutide demonstrates a favourable safety profile and significant cardiorenal benefits in CKD patients, with or without T2DM. Endocrinology, diabetes & metabolism • 2025-11-15 • Meta-Analysis | N = 12,785 | 99/100 | PMID 41276951 ↗ |
| New Insights on Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart: What a 3,668-Participant Study Found Compared with placebo, a mean atrasentan exposure translated in a hazard ratio of 0.76 (95% confidence interval (CI): 0.28-0.85) for kidney events and 1.13 (95% CI: 1.03-2.20) for heart failure events. Clinical pharmacology and therapeutics • 2021-06-15 • Phase III Randomized Trial | N = 3,668 | 96/100 | PMID 33338269 ↗ |
| New Insights on Reductions in acute medication use and healthcare resource utilization in: What a 1,113-Participant Study Found Treatment with galcanezumab resulted in significant reductions in headache medication overuse and migraine headache days requiring acute medication use, with notable reductions in migraine-specific HCRU. Journal of medical economics • 2022-01-15 • Phase III Randomized Trial | N = 1,113 | 96/100 | PMID 35971655 ↗ |
| New Insights on Empagliflozin Reduces Risk of Hospitalization in Patients With Chronic Kidney: What a 6,609-Participant Study Found 1995 participants (1035 placebo, 960 empagliflozin) had ≥1 ACH (1895 ACH in placebo and 1611 in the empagliflozin 10-mg groups). Clinical therapeutics • 2025-12-15 • Phase III Randomized Trial | N = 6,609 | 96/100 | PMID 41047325 ↗ |
| New Insights on Treatment of chronic migraine with Botox (onabotulinumtoxinA): Development,: What a 5,000-Participant Study Found Benefits also include improvements in quality of life, fewer psychiatric comorbidities, and reduced healthcare resource utilization. Medicine • 2023-07-01 • Phase III Randomized Trial | N = 5,000 | 96/100 | PMID 37499085 ↗ |
Chronic candidiasis of vulva and vagina Patient Community & “People Like Me” Threads
Filter Chronic candidiasis of vulva and vagina community threads and patient logs by age, biological sex, dosage, and treatment duration.